A priori quality assurance using a benchmark case of the randomized phase 2 GORTEC 2014-14 in oligometastatic head and neck cancer patients.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique"
DOI: 10.1016/j.canrad.2021.04.005
Abstract: PURPOSE A Benchmark Case (BC) was performed as part of the quality assurance process of the randomized phase 2 GORTEC 2014-14 OMET study, testing the possibility of multisite stereotactic radiation therapy (SBRT) alone in oligometastatic… read more here.
Keywords: quality; phase gortec; benchmark case; gortec 2014 ... See more keywords